Piperacillin Sodium (a phase III clinical trial).
Twenty-one patients with a variety of clinical infections were treated with Piperacillin Sodium intravenously. One case was considered to be a therapeutic failure. Two further cases were incapable of scientific assessment with respect to their response as no satisfactory pathogen could be identified in spite of a significant febrile illness. In all the other patients in the study a good clinical response was deemed to have been achieved. In nine of these patients, a microbiological cure was also achieved. In the remainder, because of the nature of their clinical problem, no final microbiological sample was available for culture due to the absence of any infective material. Only one adverse incident was encountered (a thrombo-phlebitis, in relation to the intravenous avenue of administration.